# **Disclosure Report**

# For the Nine Months Ended March 31, 2017

| Contacts: | Cecelia B. Moore, MHA, CPA, CHFP     | Scott T. Phillips, CPA               |
|-----------|--------------------------------------|--------------------------------------|
|           | Chief Financial Officer & Treasurer  | Vice President & Controller          |
|           | Vanderbilt University Medical Center | Vanderbilt University Medical Center |
|           | 3319 West End Avenue                 | 3319 West End Avenue                 |
|           | Nashville, TN 37203                  | Nashville, TN 37203                  |
|           | (Phone) (615) 322-0084               | (Phone) (615) 875-9078               |
|           | cecelia.b.moore@vanderbilt.edu       | scott.t.phillips@vanderbilt.edu      |

www.mc.vanderbilt.edu

#### VANDERBILT UNIVERSITY MEDICAL CENTER

**NOTICE** relating to:

THE HEALTH AND EDUCATIONAL
FACILITIES BOARD OF THE
METROPOLITAN GOVERNMENT OF
NASHVILLE AND DAVIDSON COUNTY,
TENNESSEE REVENUE BONDS
(VANDERBILT UNIVERSITY MEDICAL
CENTER) SERIES 2016A

THE HEALTH AND EDUCATIONAL
FACILITIES BOARD OF THE
METROPOLITAN GOVERNMENT OF
NASHVILLE AND DAVIDSON COUNTY,
TENNESSEE TAXABLE REVENUE BONDS
(VANDERBILT UNIVERSITY MEDICAL
CENTER) SERIES 2016B

THE HEALTH AND EDUCATIONAL
FACILITIES BOARD OF THE
METROPOLITAN GOVERNMENT OF
NASHVILLE AND DAVIDSON COUNTY,
TENNESSEE TAXABLE REVENUE BONDS
(VANDERBILT UNIVERSITY MEDICAL
CENTER) SERIES 2016C (R-FLOATS)

THE HEALTH AND EDUCATIONAL
FACILITIES BOARD OF THE
METROPOLITAN GOVERNMENT OF
NASHVILLE AND DAVIDSON COUNTY,
TENNESSEE TAXABLE REVENUE NOTE
(VANDERBILT UNIVERSITY MEDICAL
CENTER) SERIES 2016D

| CUSIP N | Nos: 592041WC7, 592041WD5, 592041WE3, 592041WF0, 592041WG8, 592041WH6, 592041WJ2, 592041RU3, 592041RV1, 592041SF5, 592041SG3, 592041XB8, 592041XC |
|---------|---|
|         |   |
|         |   |
|         |   |
|         |   |
|         |   |
|         | THE REMAINDER OF THIS PAGE WAS INTENTIONALLY LEFT BLANK   |
|         |   |
|         |   |

## **Table of Contents**

| Organization  | <u>Page</u> 3-4 |
|---|-----------------|
| Summary of Operating and Utilization Data   | 5-8             |
| Summary of Financial Data   | 9-13            |
| Consolidated Statement of Operations -<br>For the Nine months ended March 31, 2017 (Unaudited)            | 14              |
| Management Discussion and Analysis  | 15              |
| Consolidated Statement of Changes in Net Assets -<br>For the Nine months ended March 31, 2017 (Unaudited) | 16              |
| Consolidated Statement of Cash Flows -<br>For the Nine months ended March 31, 2017 (Unaudited)            | 17              |
| Consolidated Balance Sheet at March 31, 2017 (Unaudited)  | 18              |

## **ATTENTION**

This document is marked with a dated date of March 31, 2017, and reflects information only as of that date. Readers are cautioned not to assume that any information has been updated beyond the dated date except as to any portion of the document that expressly states that it constitutes an update concerning specific recent events occurring after the dated date of the document. Any information contained in the portion of the document indicated to concern recent events speaks only as of its date. We expressly disclaim any duty to provide an update of any information contained in this document.

The information contained in this document may include "forward looking statements" by using forward looking words such as "may," "will," "should," "expects," "believes," "anticipates," "estimates," or others. You are cautioned that forward looking statements are subject to a variety of uncertainties that could cause actual results to differ from the projected results. Those risks and uncertainties include general economic and business conditions, receipt of funding grants, and various other factors which are beyond our control.

Because we cannot predict all factors that may affect future decisions, actions, events, or financial circumstances, what actually happens may be different from what we include in forward looking statements.

#### **ORGANIZATION**

Vanderbilt University Medical Center ("VUMC") is a Tennessee not-for-profit corporation incorporated in March of 2015 for the purpose of operating an academic medical center and a comprehensive research, teaching, and patient care health system in the state of Tennessee (the "Medical Center"). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University ("the University" or "VU"), as a part of the University's administrative structure, with the same governing board, legal, financial, and other shared services.

VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University on April 29, 2016 (the "Acquisition"). VUMC owns and operates the three hospitals primarily located on the main campus of the University in Nashville, TN.: Vanderbilt University Adult Hospital ("VUAH"), Monroe Carell Junior Children's Hospital at Vanderbilt ("MCJCHV"), and Vanderbilt Psychiatric Hospital ("VPH"). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital ("VSRH"), also located on the main campus of the University, through a joint venture with HealthSouth Corp. in which VUMC holds a 50% interest, which includes a 1% interest held by Vanderbilt Health Services, LLC, ("VHS"), a VUMC wholly owned subsidiary. VUAH, MCJCHV, and VPH are licensed for 1,025 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration ("MCA").

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of the Vanderbilt Medical Group ("VMG"), and technical revenues and associated expenses for operation of VUMC's hospitals and clinic facilities, including VUAH, MCJCHV, and VPH. The Clinical Enterprise also includes VHS.

VUAH is a quaternary care teaching hospital licensed for 670 acute care and specialty beds. VUAH, a Level I trauma center, provides advanced patient care, and serves as a key site for medical education and clinical research conducted by physician faculty. VUAH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center.

MCJCHV is a pediatric quaternary care teaching hospital licensed for 129 acute and specialty beds, 42 Pediatric Intensive Care beds, and 96 Neonatal Intensive Care beds. MCJCHV is the region's only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

VPH is a psychiatric hospital licensed for 88 beds, and provides both inpatient and outpatient partial hospitalization psychiatric services to both adult and adolescent patients. In addition, VPH also provides psychiatric assessment services and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.

The VMG is the practice group of physicians and advanced practice nurses employed by VUMC, with faculty appointments from the University, who perform billable professional medical services. The VMG is not a separate legal entity. The VMG has a governing board which consists of the VUMC clinical service chiefs, who also serve as clinical department

chairs. Under the oversight of VUMC executive leadership, the VMG sets professional practice standards, bylaws, policies, and procedures for the administration of a group practice. VUMC bills for services rendered by the VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician's compensation.

The VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. The entire clinical faculty is "board certified" or eligible for board certification. All staff members are re-credentialed every two years by the National Committee for Quality Assurance standards. All specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.

VHS serves as a holding company for 13 health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network ("VHAN"). VHS operations primarily consist of community physician practices, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee.

The Academic Enterprise division includes all clinically-related research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC's research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the National Institutes of Health, the Department of Defense, NASA, and other federal agencies. Sponsored research awards, including multiple-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. In addition, core activities supporting research including advanced computing and grant administration are included in this division.

As mentioned above and throughout this document, VUMC acquired the Medical Center and its operations from the University in the Acquisition. For the purpose of funding the Acquisition, VUMC entered into certain debt agreements. Certain of these debt agreements contain certain required disclosures which outline annual and quarterly reporting requirements. In addition, certain of these debt agreements require notices of the occurrence of significant events which include but are not limited to delinquencies, bond calls, rating changes, bankruptcies, and mergers or acquisitions.

The VUMC fiscal year end is June 30. The information contained in this document represents the unaudited consolidated results of operations of VUMC as of and for the nine months ended March 31, 2017.

#### SUMMARY OF OPERATING AND UTILIZATION DATA

#### **Licensed Beds**

VUMC's facilities have 1,025 licensed and fully staffed beds approved for operation with 80 operating rooms, primarily located at VUAH, MCJCHV, and VPH. A fourth hospital, VSRH, is operated within a separate joint venture entity, which is currently owned 50% by VUMC. Counting VSRH beds, managed beds at Williamson County (Tennessee) Medical Center Inpatient Children's Unit, and operated observation beds and bassinet beds, total beds as of March 31, 2017, equates to 1,240.

#### **VUMC Beds (Licensed, Observation, JV, Managed)**

| <u>Licensed Beds</u>   | Available<br>Beds |
|--|-------------------|
| Licensed-Bed Category Type   |                   |
| Adult Medical Surgical   | 606               |
| Adult Obstetric  | 50                |
| Adult Clinical Research Center   | 14                |
| Pediatric Medical/Surgical   | 129               |
| Pediatric Neonatal Intensive Care  | 96                |
| Pediatric Intensive Care   | 42                |
| Psychiatric Care   | 88                |
| Total Licensed Beds as of March 31, 2017   | 1,025             |
| Observation, JV, and Managed Beds and Bassinets                                      |                   |
| Current Observation Beds   | 84                |
| Current Bassinets  | 35                |
| Stallworth Rehabilitation Hospital Beds (JV) <sup>(1)</sup>                          | 80                |
| MCJCHV at Williamson Medical Center Inpatient and Observation Unit (Managed)(2)      | 16                |
| Total Observation, JV, and Managed Beds and Bassinets as of March 31, 2017           | 215               |
| Total Licensed, Observation, JV, and Managed Beds and Bassinets as of March 31, 2017 | 1,240             |

<sup>(1)</sup> Represents 80 beds in joint venture with VSRH.

<sup>(2)</sup> Represents 12 licensed beds and four observation beds managed by VUMC with Williamson County Medical Center, Franklin, TN.

#### **VUMC Research Revenues**

VUMC receives revenues from research grants which are both federally and non-federally sponsored. The Department of Health and Human Services, the National Institutes of Health, the Department of Defense, NASA, and other federal agencies supported over 70% of the research expenditures conducted by VUMC. The breakdown of direct research revenues is as follows for the nine months ended March 31, 2017 (\$ in thousands):

#### **Source**

| Federal     | \$<br>164,450 |
|-------------|---------------|
| Non-Federal | 59,283        |
| Total       | \$<br>223,733 |

#### **Capital Cash Flows**

Capital expenditures for the nine months ended March 31, 2017, of \$100.6 million primarily included construction in progress and internal use software costs.

#### Utilization

VUMC's overall functional occupancy rate was 93.4% during the nine months ended March 31, 2017, (including observation patients in inpatient beds). The average number of inpatients in the hospital at midnight census was 882 at March 31, 2017. Thus, the Medical Center has continued to operate at or above the theoretical optimal occupancy of 85% when total utilization of capacity is measured. These high inpatient utilization rates yielded discharges of 45,602. Utilization statistics of the hospitals and clinics for the nine months ended March 31, 2017, are as follows:

| Licensed beds <sup>(1)</sup>                           | 1,025     |
|--|-----------|
| Hospital inpatient days <sup>(2)</sup>                 | 241,706   |
| Hospital discharges                                    | 45,602    |
| Average length of stay in days <sup>(2)</sup>          | 5.3       |
| Average occupancy level (licensed beds) <sup>(2)</sup> | 86.1%     |
| Surgical operations <sup>(3)</sup>                     | 44,409    |
| Ambulatory visits <sup>(4)</sup>                       | 1,705,446 |
| Emergency visits                                       | 91,762    |

- (1) Excludes nursery bassinets.
- (2) Includes nursery and psychiatric hospital; does not include observation patients.
- (3) Excludes surgical operations performed by VUMC- employed physicians at separate surgery centers that are partially owned by a VUMC subsidiary.
- (4) Includes visits related to VHS joint ventures.

#### **VUMC Inpatient Acuity**

Across all inpatients, VUMC's inpatient acuity is measured by case mix index ("CMI"). VUMC's total CMI and CMI for Medicare patients for the nine months ended March 31, 2017, are presented below:

| Total CMI <sup>(1)</sup>    | 2.16 |
|-----------------------------|------|
| Medicare CMI <sup>(1)</sup> | 2.37 |

#### (1) Excludes normal newborns.

During the nine months ended March 31, 2017, ambulatory visits at the Medical Center totaled 1,523,346 (excluding ambulatory visits from VHS joint ventures). While the majority of the VMG adult and children's ambulatory practice is located in VUAH on the main campus, VUMC health care services are offered outside the main campus, with approximately 47.7% of outpatient visits at off-campus locations during this same time period.

#### **VUMC Payor Mix**

The Medical Center received payment on behalf of most of its patients from a number of third parties, including Blue Cross and other private insurers, the federal government through Medicare, and the federal and state governments through Medicaid. TennCare, the State's managed care plan operating under a Section 1115 Medicaid demonstration waiver from the federal government, provides the majority of Medicaid revenues. The remaining Medicaid revenues are from Medicaid patients who live outside of the State. Blue Cross, one of VUMC's largest payors represented 22.7% of total gross patient service revenue (based on technical related revenue) for the nine months ended March 31, 2017.

The revenues attributable to Blue Cross are in the commercial/managed care category in the following table, which sets forth the sources of gross amounts of patient service revenue as well as gross amounts of patient service revenue net of contractual allowances for the nine months ended March 31, 2017:

| $Payor Mix^{(2)}$                      | Gross  | Net    |
|--|--------|--------|
| Commercial/Managed Care <sup>(1)</sup> | 46.0%  | 62.5%  |
| Medicare/Managed Medicare              | 30.2%  | 22.5%  |
| Tenncare/Medicaid                      | 19.6%  | 13.1%  |
| Uninsured (self-pay)                   | 4.2%   | 1.9%   |
| Total                                  | 100.0% | 100.0% |

- (1) Commercial includes commercial indemnity and other patient service programs provided under contractual arrangements.
- (2) Based on technical related revenue.

VUMC's major commercial managed care contracts are multi-year agreements, typically three to four years with automatic annual escalators. Commercial contracts reimburse the facility on case rates with stop loss provisions for inpatient medical/surgical services and fee schedules for outpatient services. VPH is reimbursed on per diems. VUMC has no agreements based on full risk or capitation reimbursement. Three major commercial contracts utilize performance on quality metrics as a basis for a portion of the annual escalators. One existing Medical Center commercial contract has two episode-based payment bundles effective July 1, 2015, with upside risk only. Over 78% of VUMC's payments for healthcare services are covered under rates contracted through fiscal year ended June 30, 2018.

The following table details payments received from VUMC's largest commercial contracts as a percentage of total net patient revenue for the nine months ended March 31, 2017, as well as the respective contract renewal date.

#### **Commercial Contract Payments as a Percentage of Total Net Patient Revenue**

|   | Total Payments <sup>(1)</sup> | Termination<br>Dates |
|---|-------------------------------|----------------------|
| Aetna                                     | 7.1%                          | 12/31/2018           |
| BlueCross                                 | 31.8%                         | 12/31/2019 (2)       |
| CIGNA                                     | 8.1%                          | 9/30/2018            |
| Humana                                    | 1.1%                          | 11/1/2018            |
| United                                    | 7.0%                          | 6/15/2017 (3)        |
| Total as a % of total net patient revenue | 55.1%                         |                      |

<sup>(1)</sup> Represents cash payments received for discharges that occurred during the nine months ended March 31, 2017. Based on technical billing payments.

Medicare Advantage contracts represented approximately \$101.7 million in net revenue or 7.1% of total net revenue (based on technical related revenue) for the nine months ended March 31, 2017, and have termination dates ranging from June 15, 2017, through December 31, 2018.

<sup>(2)</sup> If not renegotiated, contract automatically renews indefinitely.

<sup>(3)</sup> Term date extended to June 15, 2017. Contract anticipated to renew with a four year term ending on June 30, 2021. Note: Does not include behavioral or dental service contracts.

#### SUMMARY OF FINANCIAL DATA

#### **Cash and Investments**

The VUMC Board of Directors (the "Board") approves the primary investment policy, while VUMC management is responsible for appointing and removing investment managers, monitoring asset allocation within the policy guidelines, and other ongoing oversight of the investment portfolio. VUMC utilizes external investment consultants to provide professional investment analysis and guidance to assist in evaluating the performance of the fund managers. As the risk profile of VUMC matures, VUMC management anticipates undertaking modest additional risk, through asset allocation adjustments, in order to improve long-term investment returns. The table below summarizes VUMC's investment allocation as of March 31, 2017, including working capital.

#### **Summary of Cash and Investments Asset Allocation**

|                                    | Working<br>Capital | Unrestricted<br>and Restricted<br>Investments <sup>(1)</sup> | Self-<br>Insurance<br>Trust | Total |
|------------------------------------|--------------------|--|-----------------------------|-------|
| Cash & Cash Equivalents            | 71%                | 1%   | 0%                          | 54%   |
| Short-Term Investments             | 19%                | 0%   | 0%                          | 14%   |
| Equity Investments                 | 0%                 | 36%  | 56%                         | 11%   |
| Hedged Equity Investments          | 0%                 | 6%   | 5%                          | 1%    |
| Fixed Income Investments           | 10%                | 10%  | 27%                         | 11%   |
| Hedged Debt Investments            | 0%                 | 1%   | 4%                          | 1%    |
| Other Marketable Alternatives(2)   | 0%                 | 6%   | 8%                          | 1%    |
| Non-Marketable Investments         | 0%                 | 0%   | 0%                          | 0%    |
| Restricted Cash & Cash Equivalents | 0%                 | 30%  | 0%                          | 5%    |
| Bonds In Worker's Comp Account     | 0%                 | 6%   | 0%                          | 1%    |
| Split Interest Trusts              | 0%                 | 4%   | 0%                          | 1%    |
| _                                  | 100%               | 100%   | 100%                        | 100%  |

<sup>(1)</sup> Includes permanently endowed funds raised since April 30, 2016.

<sup>(2)</sup> Includes REITs and commodities.

The following table sets forth VUMC unrestricted cash and investments and days cash on hand as of March 31, 2017. This financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that will be achieved in the future (\$\sigma\$ in thousands):

#### **Summary of Unrestricted Cash and Cash Equivalents**

| Cash and cash equivalents <sup>(1)</sup>                  | \$<br>506,298 |
|---|---------------|
| Less: restricted cash and cash equivalents included above | (16,852)      |
| Total unrestricted cash and cash equivalents              | \$<br>489,446 |
|   |               |
| Unrestricted investments <sup>(2)</sup>                   | <br>284,175   |
| Total unrestricted cash and investments                   | \$<br>773,621 |
| Average daily operating expenses <sup>(3)</sup>           | \$<br>9,777   |
| Days cash on hand <sup>(4)</sup>                          | 79.1          |

- (1) Cash and cash equivalents as reported on the unaudited balance sheet.
- (2) Unrestricted investments are comprised of current and non-current investments and board designated quasi-endowment funds.
- (3) Average daily operating expenses include all VUMC financial flows to the University excluding principal payments on the Subordinated Promissory Note to VU.
- (4) Unrestricted cash and investments divided by average daily operating expenses (excluding depreciation and amortization) for the nine months then ended.

#### **Debt Service Coverage**

The following table sets forth, for the nine months ended March 31, 2017, VUMC's income available for debt service, and indicates the extent to which such income available for debt service would provide coverage for maximum annual and annual debt service on all long-term debt (\$ in thousands):

|   | Actual |          | Annualized |          |
|---|--------|----------|------------|----------|
| Excess of revenues over expenses                        | \$     | 156,962  | \$         | 209,283  |
| Less: Unrealized gains on investments <sup>(1)</sup>    |        | (8,191)  |            | (10,922) |
| Less: Unrealized gain on interest rate swap             |        | (25,956) |            | (34,608) |
| Plus: Depreciation and amortization                     |        | 67,599   |            | 90,132   |
| Plus: Interest  |        | 41,164   |            | 54,885   |
| Income available to pay debt service                    | \$     | 231,578  | \$         | 308,770  |
| Maximum annual debt service                             |        |          | \$         | 78,570   |
| Maximum annual debt service coverage <sup>(2)</sup>     |        |          |            | 3.9x     |
| Annual debt service (Scheduled) <sup>(3)</sup>          |        |          | \$         | 52,851   |
| Annual debt service coverage (Scheduled) <sup>(4)</sup> |        |          |            | 5.8x     |

<sup>(1)</sup> Excludes appreciation of endowed assets.

<sup>(2)</sup> Maximum annual debt service coverage consists of estimated annualized income available to pay debt service divided by maximum annual debt service.

<sup>(3)</sup> Represents smoothed debt service scheduled for the fiscal year. Actual payments forecasted for the fiscal year are \$41.2 million.

<sup>(4)</sup> Annual debt service coverage consists of estimated annualized income available to pay debt service divided by annual debt service.

#### **Capitalization Ratios**

The following table provides VUMC's capitalization ratios as of and for the nine months ended March 31, 2017, on an annualized basis (\$ in thousands):

| Long-Term Debt <sup>(1)</sup>                 | \$<br>1,197,525 |
|---|-----------------|
| Unrestricted Net Assets                       | 657,629         |
| Total Capitalization                          | \$<br>1,855,153 |
| Ratio of Long-Term Debt to Capitalization (%) | 64.6%           |
| EBIDA (annualized)                            | \$<br>354,300   |
| Ratio Debt to Total EBIDA <sup>(2)</sup>      | 3.4x            |
| Total Unrestricted Cash and Investments       | \$<br>773,621   |
| Ratio Cash to Debt (%) <sup>(3)</sup>         | 64.6%           |

- (1) Total outstanding long-term debt, including current maturities, excluding the Subordinate Promissory Note to VU.
- (2) Total outstanding long-term debt divided by total EBIDA, which includes realized gains from sale of assets incurred in the normal course of operations, investment income (all gains), unrestricted gifts or restricted gifts released from restrictions (spent on the purpose), unrealized gain or loss on interest rate swap, and equity earnings in unconsolidated organizations.
- (3) Unrestricted cash and investments divided by long-term debt, which includes unrestricted cash and cash equivalents and unrestricted investments.

#### **Interest Rate Exchange Agreements**

VUMC uses interest rate exchange agreements as part of its debt portfolio management strategy. These agreements do not include collateral pledging requirements. Mandatory termination provisions on each agreement are shown below with information regarding the current interest rate exchange agreements as follows (\$ in thousands):

|                               | <b>Notional</b> |           | Rate      |                 | Fair      |
|-------------------------------|-----------------|-----------|-----------|-----------------|-----------|
| Description                   | Amount          | Rate Paid | Received  | <b>Maturity</b> | Value     |
| Fixed-payer interest          |                 |           |           |                 |           |
| rate agreement(1)             | \$ 75,000       | 4.119%    | 68% LIBOR | 5/1/2040        | \$ 31,950 |
| Fixed-payer interest          |                 |           |           |                 |           |
| rate agreement <sup>(2)</sup> | \$ 75,000       | 4.179%    | 68% LIBOR | 5/1/2040        | 31,630    |
|                               |                 |           |           |                 | \$ 63,580 |

- (1) Includes a mandatory termination provision on April 29, 2021.
- (2) Includes a mandatory termination provision on April 29, 2023.

## **Existing Lease Agreements**

VUMC leases certain property and equipment under leases with terms ranging from two to twenty years. In addition, VUMC is the lessor in a 99 year ground lease with Vanderbilt University. VUMC classifies these leases as operating leases. The following is a schedule by fiscal year of future minimum rentals on non-cancelable operating leases as of March 31, 2017 (\$ in thousands):

|            | Equ | uipment | Pre | operty  | <b>Ground Lease</b> |           | <br><b>Total</b> |  |
|------------|-----|---------|-----|---------|---------------------|-----------|------------------|--|
| 2017       | \$  | 7,025   | \$  | 11,104  | \$                  | 4,500     | \$<br>22,629     |  |
| 2018       |     | 18,084  |     | 44,254  |                     | 18,000    | 80,338           |  |
| 2019       |     | 13,782  |     | 43,381  |                     | 18,000    | 75,163           |  |
| 2020       |     | 9,077   |     | 41,886  |                     | 18,000    | 68,963           |  |
| 2021       |     | 6,135   |     | 33,729  |                     | 18,000    | 57,864           |  |
| Thereafter |     | 7,062   |     | 194,022 |                     | 1,692,000 | <br>1,893,084    |  |
| Total      | \$  | 61,165  | \$  | 368,376 | \$                  | 1,768,500 | \$<br>2,198,041  |  |

# CONSOLIDATED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED MARCH 31, 2017

# (Unaudited) (\$ in thousands)

| Operating Revenue   |              |
|---|--------------|
| Net patient service revenue, net of provision for bad debts | \$ 2,465,101 |
| Academic and research revenue                               | 281,237      |
| Other operating revenue                                     | 99,523       |
| Total operating revenue                                     | 2,845,861    |
| Operating Expenses  |              |
| Salaries, wages and benefits                                | 1,523,587    |
| Supplies and drugs  | 524,008      |
| Facilities and equipment                                    | 176,414      |
| Purchased services and other expense                        | 411,212      |
| Depreciation and amortization expense                       | 67,599       |
| Interest  | 41,164       |
| Total operating expense                                     | 2,743,984    |
| Income from operations                                      | 101,877      |
| Non-operating Revenue & Expense                             |              |
| Income from investments                                     | 16,243       |
| Gift income   | 10,014       |
| Earnings of unconsolidated organizations                    | 2,872        |
| Unrealized gain from interest rate swap                     | 25,956       |
| Total non-operating revenue & expense                       | 55,085       |
| Excess of revenues over expenses                            | \$ 156,962   |

#### MANAGEMENT DISCUSSION AND ANALYSIS

Income from operations and excess of revenue over expenses for the nine months ended March 31, 2017, was \$101.9 million and \$157.0 million, respectively. Additionally, earnings before interest, depreciation, and amortization (EBIDA) including non-operating, as calculated in the "Summary of Financial Data" section of this document, totaled \$265.7 million for the same period.

#### Revenues

Operating revenues totaled approximately \$2,845.9 million for the nine months ended March 31, 2017. Net patient service revenue, net of bad debts, totaled \$2,465.1 million representing 86.6% of operating revenue. VUMC inpatient discharges were 45,602 for the nine month period ended March 31, 2017. Over the same period, inpatient and outpatient surgical cases excluding surgical operations performed by VUMC- employed physicians at separate surgery centers that are partially owned by a VUMC subsidiary were 16,169 and 28,240, respectively. VUMC's inpatient acuity, measured by CMI (excluding normal newborns) for Medicare patients and in total was 2.37 and 2.16, respectively, during the nine months ended March 31, 2017. During the nine months ended March 31, 2017, ambulatory visits at VUMC totaled 1,705,446 including visits from VHS joint ventures.

#### **Expenses**

Operating expense totaled approximately \$2,744.0 million for the nine months ended March 31, 2017, representing 96.4% of total revenue. Salaries, wages, and benefits totaled approximately \$1,523.6 million representing 53.5% of total operating revenue. Supplies and drugs totaled approximately \$524.0 million representing 18.4% of total operating revenue. Purchased services and other expense totaled approximately \$411.2 million representing 14.4% of operating revenue. The remaining \$285.2 million in operating expenses represents facilities and equipment, depreciation and amortization, and interest.

#### **Non-operating**

The non-operating income for the period was primarily driven by investment income (including unrealized) and income from the interest rate swaps of \$16.2 million and \$26.0 million, respectively.

#### **Balance Sheet / Cash Flow**

Cash and cash equivalents totaled approximately \$506.3 million at March 31, 2017, compared to cash of \$603.1 million as of June 30, 2016. The primary drivers of the decrease in cash were net investment purchases of \$211.6 million and capital expenditures of \$100.6 million partially offset by excess revenues over expenses before depreciation and amortization for the nine months ended March 31, 2017, of \$224.6 million (excess revenue over expense of \$157.0 million plus depreciation and amortization of \$67.6 million).

# CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS FOR THE NINE MONTHS ENDED MARCH 31, 2017

# (Unaudited) (\$ in thousands)

| Excess of revenue over expense                 | \$<br>156,962 |
|--|---------------|
| Change in noncontrolling interest's net assets | 56            |
| Net asset reclassification                     | (8,031)       |
| Other changes                                  | (779)         |
| Total changes in unrestricted net assets       | 148,208       |
| Changes in temporarily restricted net assets   |               |
| Contributions                                  | 17,242        |
| Net assets released from restrictions          | (3,312)       |

# Total changes in temporarily restricted net assets Changes in permanently restricted net assets

Changes in unrestricted net assets

Net asset reclassification

| Contributions                                      |         | 4,614   |
|--|---------|---------|
| Net asset reclassification                         |         | 781     |
| Total changes in permanently restricted net assets |         | 5,395   |
| Total changes in net assets                        | <u></u> | 174 783 |

7,250

21,180

### CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE NINE MONTHS ENDED MARCH 31, 2017 (Unaudited)

## (\$ in thousands)

## **Cash Flows from Operating Activities:**

| cush riows from Operating retrities.                              |    |           |
|---|----|-----------|
| Total change in net assets  | \$ | 174,783   |
| Adjustments to reconcile increase in net assets to                |    |           |
| net cash provided by operating activities:                        |    |           |
| Depreciation and amortization                                     |    | 67,599    |
| Loss on disposal of assets  |    | 1,415     |
| Gain on equity method investee                                    |    | (678)     |
| Net unrealized gain on investments                                |    | (8,191)   |
| (Decrease) increase in cash due to changes in:                    |    |           |
| Patient accounts receivable                                       |    | (49,606)  |
| Inventory   |    | (510)     |
| Prepaid expenses  |    | 3,523     |
| Accounts payable and accrued expense                              |    | 13,412    |
| Estimated net receivables and payables – third-party              |    | 15,768    |
| Accrued compensation and benefits                                 |    | (21,720)  |
| Other assets  |    | 48,471    |
| Other liabilities   |    | (25,039)  |
| Net cash provided by operating activities                         |    | 219,227   |
| Cash Flows from Investing Activities:                             |    |           |
| Purchase of property, plant and equipment                         |    | (100,627) |
| Purchase of investments   |    | (211,636) |
| Net cash used in investing activities                             |    | (312,263) |
| Cash Flows from Financing Activities:                             |    |           |
| Principal payments on long-term debt                              |    | (3,750)   |
| Net cash used in financing activities                             |    | (3,750)   |
| Net change in unrestricted cash and cash equivalents              |    | (96,786)  |
| Unrestricted cash and cash equivalents at beginning of the period |    | 603,084   |
| Unrestricted cash and cash equivalents at end of the period       | \$ | 506,298   |
|   | ·  |           |

# CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2017

# (Unaudited) (\$ in thousands)

| (\$ in thousands)  |    |                    |
|--|----|--------------------|
| Assets   |    |                    |
| Current  | ¢. | 506 200            |
| Cash and cash equivalents  | \$ | 506,298            |
| Current investments  Patient accounts receivable, not of allowance for had debts                             |    | 132,451<br>392,847 |
| Patient accounts receivable, net of allowance for bad debts Estimated receivables under third-party programs |    | 31,315             |
| Current pledge receivable, net   |    | 5,851              |
| Grants and contracts receivable, net   |    | 56,902             |
| Inventories  |    | 62,435             |
| Prepaid expenses   |    | 5,031              |
| Other current assets   |    | 28,764             |
| Total current assets   |    | 1,221,894          |
| Non-current investments  |    | 64,714             |
| Non-current investments limited as to use  |    | 213,029            |
| Non-current pledge receivable, net   |    | 7,882              |
| Equity in unconsolidated organizations   |    | 19,706             |
| Property, plant, and equipment, net  |    | 1,168,057          |
| Other non-current assets   |    | 5,679              |
| Total assets   | \$ | 2,700,961          |
| Liabilities and Net Assets   |    |                    |
| Current  |    |                    |
| Current installments of long-term debt   | \$ | 5,000              |
| Accounts payable and other accrued expenses  |    | 242,918            |
| Estimated payables under third-party programs  |    | 68,950             |
| Accrued compensation and benefits  |    | 178,390            |
| Current portion of deferred revenue  |    | 43,408             |
| Current portion of self-insurance reserves and claims  |    | 20,657             |
| Other current liabilities  |    | 203                |
| Total current liabilities  |    | 559,526            |
| Non-current portion of deferred revenue  |    | 6,440              |
| Non-current portion of self-insurance reserves and claims  |    | 61,670             |
| Fair value of interest rate exchange agreements  |    | 63,580             |
| Long-term debt, net of current installments  |    | 1,288,358          |
| Other non-current liabilities  |    | 3,429              |
| Total liabilities  |    | 1,983,003          |
| Net assets   |    |                    |
| Unrestricted net assets controlled by Vanderbilt University Medical Center                                   |    | 652,046            |
| Unrestricted net assets related to noncontrolling interests  |    | 5,583              |
| Total unrestricted net assets  |    | 657,629            |
| Temporarily restricted net assets  |    | 48,165             |
| Permanently restricted net assets  |    | 12,164             |
| Total net assets   |    | 717,958            |
| Total liabilities and net assets   | \$ | 2,700,961          |